Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C
The DOI matches its Crossref record.
Abstract
Background & Aims: Fibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N‐terminal propeptide of type III collagen (Pro‐C3) and a peptide of helical collagen type III degradation (C3M), in chronic hepatitis C (CHC) patients. Method: Pro‐C3 and C3M were measured by ELISA in plasma from CHC patients (n = 194) from a prior phase II antifibrotic trial (NCT 00244751). Plasma samples and paired liver biopsies were obtained at baseline and after 1‐year. Patients were stratified according to Ishak stages 2‐4. Internal cross‐validation was performed by bootstrap analysis. Results: Pro‐C3 levels were significantly higher in CHC patients in Ishak stage 4 compared to stage 2 (P < 0.001) or 3 (P < 0.01). Pro‐C3 could significantly distinguish moderate (stage 4) from mild fibrosis (stage 2/3) (AUC = 0.72, P < 0.001). Importantly, an overall significance in Pro‐C3 (P = 0.007) levels was observed between the groups of −1, 0, +1 and +2 change in Ishak stage at 12 months. Pro‐C3 was significantly increased in group +1 (P = 0.030) and +2 (P = 0.021) compared to group 0. No significant differences were observed for C3M. In multivariate analysis, only baseline Pro‐C3, but not FibroTest, had an independent association with fibrosis progression. Conclusions: Pro‐C3 is a useful test to predict fibrogenesis and monitor disease progression. Moreover, it could differentiate mild from moderate disease. Pro‐C3 may become a promising blood parameter be included in future studies for monitoring disease progression and eventually for evaluation of potential antifibrotic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vilar-Gomez, E., & Chalasani, N. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.013 · Cited by 610
Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Determinants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
“47,51-53), and, more importantly, the dynamics of fibrogenesis and fibrolysis (54-59).”
BackgroundSelf-citationDaniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., Karsdal, M. A., Grove, J. I., Neil Guha, I., Kawaguchi, T., et al. (2019) · Hepatology · doi:10.1002/hep.30163 · Cited by 273
“Here we demonstrate that PRO-C3, which measures type III collagen synthesis, is a precise marker for advanced liver fibrosis in concordance with what we have recently shown in chronic hepatitis C.(22,31,32) Notably, a recent small nonbiopsy study (n = 297) from a phase III study of balaglitazone in patients with late-…”
ResultSelf-citation
Metadata
- Authors
- Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Ørsnes‐Leeming, D. J., Vainer, B., Gardner, S. D., Hamatake, R., Goodman, Z. D., Schuppan, D., & Patel, K.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2014-10-29
- Volume
- 35
- Issue
- 2
- Pages
- 429-437
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2125971163
- Cited by
- 144
- References
- 0
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. https://app.cochat.ai/papers/10.1111/liv.12700
- The paper
- Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Ørsnes‐Leeming, D. J., Vainer, B., Gardner, S. D., Hamatake, R., Goodman, Z. D., Schuppan, D., & Patel, K. (2015). Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver International. https://doi.org/10.1111/liv.12700
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.